Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 63; no. 4; p. 449
• Main Authors: Ruane, Peter J, DeJesus, Edwin, Berger, Daniel, Markowitz, Martin, Bredeek, U Fritz, Callebaut, Christian, Zhong, Lijie, Ramanathan, Srini, Rhee, Martin S, Fordyce, Marshall W, Yale, Kitty
• Format: Journal Article
• Language: English
• Published: United States 01.08.2013
• Subjects: Adenine - adverse effects; Adenine - analogs & derivatives; Adenine - blood; Adenine - pharmacokinetics; Adenine - pharmacology; Adenine - therapeutic use; Adult; Anti-Retroviral Agents - pharmacokinetics; Anti-Retroviral Agents - pharmacology; Anti-Retroviral Agents - therapeutic use; Area Under Curve; Dose-Response Relationship, Drug; Fatigue - chemically induced; Female; HIV Infections - blood; HIV Infections - drug therapy; HIV-1; Humans; Male; Middle Aged; Nausea - chemically induced; Organophosphates - blood; Organophosphonates - pharmacokinetics; Organophosphonates - pharmacology; Organophosphonates - therapeutic use; RNA, Viral - blood; Single-Blind Method; Statistics, Nonparametric; Tenofovir; Viral Load; Young Adult

To evaluate the antiviral activity, safety, pharmacokinetics, and pharmacokinetics/pharmacodynamics of short-term monotherapy with tenofovir alafenamide (TAF), a next-generation tenofovir (TFV) prodrug. A phase 1b, randomized, partially blinded, active- and placebo-controlled, dose-ranging study. Tr...